Bms-844203

Colorectal Cancer (CRC)

Bristol-Myers SquibbPhase 2Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 73/ 100

Competitive context

840 Active assets in the Colorectal Cancer (CRC) cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
MARBLE DUST James Varani	Phase 2/3	BB
FLUOROURACILUM Washington University School of Medicine	Phase 4	BB
PANITUMUMAB M.D. Anderson Cancer Center	Phase 3	BB
Cetuximab Shanghai Henlius Biotech	Phase 4	BB

View all 50 →

Same molecule, other indications

Bms-844203 is also rated in:

glioblastomaDormant

B

Indicative ·

58 / 100

central nervous system neoplasmDormant

CCC

Indicative ·

53 / 100

non-small cell lung carcinomaDormant

CCC

Indicative ·

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.